We further utilized Wnt/β-catenin pathway-specific inhibitors XAV-939 to confirm the involvement of the Wnt/β-catenin axis on REG1α-stimulated glycolysis and malignant tumor phenotypes in CRC. The gene discussed is REG1A; the disease is neoplasm.